Search

Minerva Neurosciences Inc

Open

2.45 -4.3

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.31

Max

2.6

Belangrijke statistieken

By Trading Economics

Inkomsten

143M

17M

Werknemers

7

EBITDA

-11M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+251.24% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-75M

97M

Vorige openingsprijs

6.75

Vorige sluitingsprijs

2.45

Minerva Neurosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 nov 2026, 23:56 UTC

Morningstar, Inc. is showing little change in after-market trading, having peaked at a modest increase after starting the session down significantly.

9 nov 2026, 23:56 UTC

National Healthcare Corp is advancing in after-market trading, significantly above the lower end of its one-month trading range since Monday's close.

9 nov 2026, 23:56 UTC

Globus Medical, Inc. is trading lower in after-market hours, continuing a downward trend from Monday's close and near the lower end of its one-month range.

9 nov 2026, 23:56 UTC

McCormick & Company shares advanced modestly higher in after-market hours, rebounding from an initial dip to close at the higher end of its recent range.

9 nov 2026, 23:56 UTC

Powell Industries Inc is trading modestly higher in after-market hours, recovering from a significant dip earlier in the session.

9 nov 2026, 23:56 UTC

Correlated Moves

ONEOK Inc. shares advanced modestly in after-market hours, influenced by a higher move in Kinetik Holdings Inc., which has a historical correlation with ONEOK.

9 nov 2026, 23:56 UTC

Wendy's Co shares are trading higher in after-market hours, maintaining a level just above Monday's close amid a strong broader market context.

9 nov 2026, 23:56 UTC

Event

Allogene Therapeutics announces preliminary safety and efficacy data from its Phase 1 RESOLUTION study for ALLO-329, an investigational CAR T product.

9 nov 2026, 23:52 UTC

Carlisle Companies Incorporated shares are trading lower in after-market hours, shifting from a slight gain to a notable loss.

9 nov 2026, 23:51 UTC

Franklin Street Properties Corp is trading sharply higher in after-market hours, reaching a notable peak after starting flat following Monday's close.

9 nov 2026, 23:51 UTC

Howmet Aerospace Inc. is advancing in after-market trading, supported by stronger-than-expected U.S. wholesale inventories and cautious Federal Reserve remarks on monetary policy.

9 nov 2026, 23:51 UTC

NIO Inc. has seen modest gains in after-market trading, rising steadily and positioning the stock above its 20-day moving average.

9 nov 2026, 23:51 UTC

Schrodinger Inc shares are trading modestly lower in after-market hours, following a notable dip shortly after the regular session ended.

9 nov 2026, 23:51 UTC

Organon & Co. shares are trading modestly lower during after-market hours, positioned near the lower end of their one-month trading range amid ongoing performance weakness.

9 nov 2026, 23:51 UTC

News

Jefferies maintains a Buy rating on Airbnb, Inc. and raises its price target to $230, citing confidence in the company's growth prospects.

9 nov 2026, 23:51 UTC

Primerica, Inc. has gained modestly in after-market trading, reaching its highest cumulative return since Monday's close with strong momentum and five consecutive higher daily closes.

9 nov 2026, 23:51 UTC

UK Retail Sales Monitor YoY for October 2026 Expected to Show Modest Growth Amid Economic Caution and Inflationary Pressures

9 nov 2026, 23:51 UTC

Japan's Household Spending Plummets 2.8% in September, Sparking Concerns Over Economic Health and Consumer Confidence

9 nov 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Index drops to 82.6, signaling continued decline in consumer sentiment amid economic uncertainties.

9 nov 2026, 23:51 UTC

Japan's household spending plunges 6.8% YoY in September, worse than expected, sparking a 3.2% rise in Nikkei futures amid ongoing economic concerns.

9 nov 2026, 23:51 UTC

Australia's Consumer Confidence Rises 2.7% Amid Ongoing Economic Concerns, Yet Sentiment Remains Fragile

9 nov 2026, 23:51 UTC

News

EVI Industries reports Q1 earnings of $0.24 per share, exceeding estimates, with revenue of $112.948 million and a 108% increase in net income to $3.847 million.

9 nov 2026, 23:51 UTC

Fluor Corp shares are declining in after-market trading, pulling back from a brief peak shortly after the market closed.

9 nov 2026, 23:51 UTC

Archer-Daniels-Midland Co is trading modestly higher in after-market hours, having shown notable strength earlier in the session.

9 nov 2026, 23:51 UTC

News
Event

Mesa Laboratories reports Q2 net income of $4.34 million, revenue of $62.34 million, and projects full-year revenue of $250M to $255M.

9 nov 2026, 23:51 UTC

Aquestive Therapeutics, Inc. shares are rising in after-market hours, supported by positive U.S. wholesale inventory data and easing geopolitical tensions affecting crude oil prices.

9 nov 2026, 23:51 UTC

Kimberly-Clark Corporation shares declined in after-market trading, reversing earlier gains and remaining modestly lower compared to Monday's close.

9 nov 2026, 23:51 UTC

Walt Disney Company shares are modestly lower in after-market hours, following a notable decline from earlier highs reached shortly after the market closed.

9 nov 2026, 23:51 UTC

Correlated Moves

TTM Technologies Inc shares are higher in after-market trading, following a notable rise in Sanmina Corporation after it reported strong fourth-quarter results.

9 nov 2026, 23:51 UTC

Social Media

Children's Place Inc shares fell sharply in after-market hours following news of its Chapter 11 bankruptcy filing and plans to seek bids by December 9.

Peer Vergelijking

Prijswijziging

Minerva Neurosciences Inc Prognose

Koersdoel

By TipRanks

251.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.5 USD  251.24%

Hoogste 10 USD

Laagste 7 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Minerva Neurosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
help-icon Live chat